Nicorandil Enhances Myocardial Tolerance to Ischemia Without Progressive Collateral Recruitment During Coronary Angioplasty.

Nicorandil-Induced Preconditioning as Evidenced by Troponin T Measurements after Coronary Angioplasty in Patients with Stable Angina Pectoris.

“…14) We have revealed that nicorandil-induced preconditioning during coronary angioplasty is independent of collateral recruitment using the same CFI. 24) CFI in the present study indicates that not only were there no significant differences in collateral recruitment between the two groups, which may influence TnT release, but also that the pharmacological preconditioning of nicorandil did not involve progressive collateral recruitment.…”

Myocardial Protective Effects of Nicorandil During Percutaneous Coronary Intervention in Patients With Unstable Angina

“…Nicorandil has a function similar to ischemic preconditioning and is known to reduce the size of the infarct and promote the recovery of systolic function after infarction. [26][27][28][29][30] The Impact of Nicorandil in Angina research, which was a large-scale study of the myocardial protective effect of nicorandil in the high-risk group of patients with stable angina, reported that 13.1% of patients who had oral nicorandil died from coronary artery disease or were admitted unexpectedly for non-fatal myocardial infarction or chest pains, which was significantly lower than the 15.5% of patients who given placebo, so nicorandil could improve prognosis in stable angina. 9 In one study of patients with UAP, Patel et al reported that the frequencies of transient myocardial ischemia, ventricular tachycardia and supraventricular tachycardia were reduced in patients who had oral nicorandil.…”

Sarpogrelate, a 5-HT2 Receptor Blocker, may Have a Preconditioning-Like Effect in Patients With Coronary Artery Disease

“…9 Recently, we showed that sarpogrelate reduced the size of the myocardial infarct in rabbit hearts without collateral circulation, and that the same mechanism as ischemic preconditioning (IPC), from the translocation of protein kinase C (PKC) to the opening of mitochondrial KATP channels, plays an important role in the protective effect. 10 We also previously reported that nicorandil, a hybrid nitrate with a KATP channel opening effect, which is currently used clinically as an anti-anginal and cardioprotective drug, 11,12 has a pharmacological preconditioning (PC) effect during percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD). 13 Therefore, the aim of the present study was to clarify the anti-ischemic effect of sarpogrelate and its mechanism using a similar PCI model in patients with CAD.…”